Replies to post #139825 on Biotech Values

[DewDiligence]

The key passage from your EASL post:

[Based on ABT’s results to date], “to be competitive, regimens must be interferon-free, 12 weeks in duration, and produce 90% SVR in [treatment]-naïve patients and 50%+ SVR in treatment-experienced.”

It’s instructive to compare the above assertion to the results of the iHub survey in #msg-72445229, bearing in mind that the survey question referred to a 2-drug regimen, specifically.

[DewDiligence]

ABT’s HCV data to be presented at EASL will not differ materially from what was disclosed in the abstracts, according to today’s CC.